REG - SkinBioTherapeutics - Reconfirmation of Market Guidance and AGM Q&A

SkinbiotherapeuticsAnnouncement

18/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251218:nRSR0254Ma&default-theme=true

RNS Number : 0254M  SkinBioTherapeutics PLC  18 December 2025

 

SkinBioTherapeutics plc
("SkinBioTherapeutics" or the "Group" or the "Company")

 

Reconfirmation of Market Guidance and AGM Shareholder Information

 

18 December 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group
focused on skin health, confirms that overall trading of the Group has started
very positively for the new financial year. Consequently, the Board still
anticipates reporting 2026 full year numbers in line with market
expectations*.

In addition, in response to some shareholder questions about the upcoming AGM,
the Directors have provided a Q&A within the Shareholder Circulars section
of the Shareholder Information page [H
(https://www.skinbiotherapeutics.com/investor-relations/shares-in-issue-shareholder-information/)
ere
(https://www.skinbiotherapeutics.com/investor-relations/shares-in-issue-shareholder-information/)
].

* Market expectations for the year ending 30 June 2026: revenue of £6.2
million and adjusted EBITDA of £0.7 million

 

-Ends-

 

For more information please contact:

 SkinBioTherapeutics plc                                  +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

Emily Bertram, Group Finance Director
 Singer Capital Markets (Nominated Adviser & Broker)      +44 (0) 020 7496 3000

 Philip Davies

James Todd

Patrick Weaver
 Vigo Consulting (financial press)                        +44 (0) 20 7390 0230

 Rozi Morris, Melanie Toyne-Sewell                        SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix(®), is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare
(SkinBiotix(®)) and food supplements that harness the gut-skin axis
(AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where
SkinBiotix(®) is being used as an active skin ingredient with the Croda trade
name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting
the symptoms of inflammatory skin conditions, being sold directly and via
Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skincare and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFSIFELDLIE



            Copyright 2019 Regulatory News Service, all rights reserved